Cargando…
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
BACKGROUND: Preliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of select psychedelics (e.g., psilocybin) suggest that their effects are transdiagnostic. In this review, we exploit the Research Domain Criteria (RDoC) transdiagnostic f...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550777/ https://www.ncbi.nlm.nih.gov/pubmed/36097251 http://dx.doi.org/10.1007/s40263-022-00944-y |
_version_ | 1784805957063147520 |
---|---|
author | Pouyan, Niloufar Halvaei Khankahdani, Zahra Younesi Sisi, Farnaz Lee, Yena Rosenblat, Joshua D. Teopiz, Kayla M. Lui, Leanna M. W. Subramaniapillai, Mehala Lin, Kangguang Nasri, Flora Rodrigues, Nelson Gill, Hartej Lipsitz, Orly Cao, Bing Ho, Roger Castle, David McIntyre, Roger S. |
author_facet | Pouyan, Niloufar Halvaei Khankahdani, Zahra Younesi Sisi, Farnaz Lee, Yena Rosenblat, Joshua D. Teopiz, Kayla M. Lui, Leanna M. W. Subramaniapillai, Mehala Lin, Kangguang Nasri, Flora Rodrigues, Nelson Gill, Hartej Lipsitz, Orly Cao, Bing Ho, Roger Castle, David McIntyre, Roger S. |
author_sort | Pouyan, Niloufar |
collection | PubMed |
description | BACKGROUND: Preliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of select psychedelics (e.g., psilocybin) suggest that their effects are transdiagnostic. In this review, we exploit the Research Domain Criteria (RDoC) transdiagnostic framework, to synthesize extant literature on psilocybin. OBJECTIVE: We aimed to identify RDoC-based effects of psilocybin and vistas for future mechanistic and interventional research. METHODS: A systematic search in electronic databases (i.e., PubMed, Scopus, PsycINFO, and Web of Science) performed in January and February 2021 identified English articles published between 1990 and 2020 reporting the effects of psilocybin on mental health measures. Data from included articles were retrieved and organized according to the RDoC bio-behavioral matrix and its constituent six main domains, namely: positive valence systems, negative valence systems, cognitive systems, social processes, sensorimotor systems, and arousal and regulatory systems. RESULTS: The preponderance of research with psilocybin has differentially reported beneficial effects on positive valence systems, negative valence system, and social process domains. The data from the included studies support both short-term (23 assessments) and long-term (15 assessments) beneficial effects of psilocybin on the positive valence systems. While 12 of the extracted outcome measures suggest that psilocybin use is associated with increases in the “fear” construct of the negative valence systems domain, 19 findings show no significant effects on this construct, and seven parameters show lowered levels of the “sustained threat” construct in the long term. Thirty-four outcome measures revealed short-term alterations in the social systems’ construct namely, “perception and understanding of self,” and “social communications” as well as enhancements in “perception and understanding of others” and “affiliation and attachment”. The majority of findings related to the cognitive systems’ domain reported dyscognitive effects. There have been relatively few studies reporting outcomes of psilocybin on the remaining RDoC domains. Moreover, seven of the included studies suggest the transdiagnostic effects of psilocybin. The dashboard characterization of RDoC outcomes with psilocybin suggests beneficial effects in the measures of reward, threat, and arousal, as well as general social systems. CONCLUSIONS: Psilocybin possesses a multi-domain effectiveness. The field would benefit from highly rigorous proof-of-mechanism research to assess the effects of psilocybin using the RDoC framework. The combined effect of psilocybin with psychosocial interventions with RDoC-based outcomes is a priority therapeutic vista. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40263-022-00944-y. |
format | Online Article Text |
id | pubmed-9550777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-95507772022-10-12 A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review Pouyan, Niloufar Halvaei Khankahdani, Zahra Younesi Sisi, Farnaz Lee, Yena Rosenblat, Joshua D. Teopiz, Kayla M. Lui, Leanna M. W. Subramaniapillai, Mehala Lin, Kangguang Nasri, Flora Rodrigues, Nelson Gill, Hartej Lipsitz, Orly Cao, Bing Ho, Roger Castle, David McIntyre, Roger S. CNS Drugs Systematic Review BACKGROUND: Preliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of select psychedelics (e.g., psilocybin) suggest that their effects are transdiagnostic. In this review, we exploit the Research Domain Criteria (RDoC) transdiagnostic framework, to synthesize extant literature on psilocybin. OBJECTIVE: We aimed to identify RDoC-based effects of psilocybin and vistas for future mechanistic and interventional research. METHODS: A systematic search in electronic databases (i.e., PubMed, Scopus, PsycINFO, and Web of Science) performed in January and February 2021 identified English articles published between 1990 and 2020 reporting the effects of psilocybin on mental health measures. Data from included articles were retrieved and organized according to the RDoC bio-behavioral matrix and its constituent six main domains, namely: positive valence systems, negative valence systems, cognitive systems, social processes, sensorimotor systems, and arousal and regulatory systems. RESULTS: The preponderance of research with psilocybin has differentially reported beneficial effects on positive valence systems, negative valence system, and social process domains. The data from the included studies support both short-term (23 assessments) and long-term (15 assessments) beneficial effects of psilocybin on the positive valence systems. While 12 of the extracted outcome measures suggest that psilocybin use is associated with increases in the “fear” construct of the negative valence systems domain, 19 findings show no significant effects on this construct, and seven parameters show lowered levels of the “sustained threat” construct in the long term. Thirty-four outcome measures revealed short-term alterations in the social systems’ construct namely, “perception and understanding of self,” and “social communications” as well as enhancements in “perception and understanding of others” and “affiliation and attachment”. The majority of findings related to the cognitive systems’ domain reported dyscognitive effects. There have been relatively few studies reporting outcomes of psilocybin on the remaining RDoC domains. Moreover, seven of the included studies suggest the transdiagnostic effects of psilocybin. The dashboard characterization of RDoC outcomes with psilocybin suggests beneficial effects in the measures of reward, threat, and arousal, as well as general social systems. CONCLUSIONS: Psilocybin possesses a multi-domain effectiveness. The field would benefit from highly rigorous proof-of-mechanism research to assess the effects of psilocybin using the RDoC framework. The combined effect of psilocybin with psychosocial interventions with RDoC-based outcomes is a priority therapeutic vista. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40263-022-00944-y. Springer International Publishing 2022-09-12 2022 /pmc/articles/PMC9550777/ /pubmed/36097251 http://dx.doi.org/10.1007/s40263-022-00944-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Systematic Review Pouyan, Niloufar Halvaei Khankahdani, Zahra Younesi Sisi, Farnaz Lee, Yena Rosenblat, Joshua D. Teopiz, Kayla M. Lui, Leanna M. W. Subramaniapillai, Mehala Lin, Kangguang Nasri, Flora Rodrigues, Nelson Gill, Hartej Lipsitz, Orly Cao, Bing Ho, Roger Castle, David McIntyre, Roger S. A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review |
title | A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review |
title_full | A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review |
title_fullStr | A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review |
title_full_unstemmed | A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review |
title_short | A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review |
title_sort | research domain criteria (rdoc)-guided dashboard to review psilocybin target domains: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550777/ https://www.ncbi.nlm.nih.gov/pubmed/36097251 http://dx.doi.org/10.1007/s40263-022-00944-y |
work_keys_str_mv | AT pouyanniloufar aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT halvaeikhankahdanizahra aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT younesisisifarnaz aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT leeyena aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT rosenblatjoshuad aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT teopizkaylam aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT luileannamw aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT subramaniapillaimehala aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT linkangguang aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT nasriflora aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT rodriguesnelson aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT gillhartej aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT lipsitzorly aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT caobing aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT horoger aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT castledavid aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT mcintyrerogers aresearchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT pouyanniloufar researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT halvaeikhankahdanizahra researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT younesisisifarnaz researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT leeyena researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT rosenblatjoshuad researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT teopizkaylam researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT luileannamw researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT subramaniapillaimehala researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT linkangguang researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT nasriflora researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT rodriguesnelson researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT gillhartej researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT lipsitzorly researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT caobing researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT horoger researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT castledavid researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview AT mcintyrerogers researchdomaincriteriardocguideddashboardtoreviewpsilocybintargetdomainsasystematicreview |